The Bcl-2 family of proteins is the main controller of the intrinsic (mitochondrial) pathway of apoptosis. Every cell constantly receives two kinds of signals: ones that say “survive” and ones that say “die.” The Bcl-2 family weighs these signals and makes the final decision at the mitochondria — should the cell live or should it undergo apoptosis?
The family gets its name from B-cell lymphoma-2 (BCL-2). This was the first member discovered. It was found in a type of lymphoma where chromosomes 14 and 18 had swapped pieces (a translocation). BCL-2 was unusual for a cancer-causing protein — it did not make cells divide faster. Instead, it stopped cells from dying. That allowed lymphoma cells to survive forever. This discovery changed how cancer biologists think about tumour growth.
Every member of the Bcl-2 family shares at least one part called a Bcl-2 Homology (BH) domain. How many BH domains a protein has, and which ones, decides which subfamily it belongs to — and whether it promotes life or death for the cell.
Structural Hallmark: The BH Domains
There are four BH domains: BH1, BH2, BH3, and BH4.
- The binding groove: BH1, BH2, and BH3 fold together to make a hydrophobic (water-hating) groove on the surface of anti-apoptotic proteins. This groove is like a pocket that grabs the BH3 domain of other family members, holding them inactive.
- The survival marker: BH4 domain is present only in anti-apoptotic proteins. No pro-apoptotic protein ever has BH4. So if you see BH4, you know the protein is a survival protein.
- The death helix: The BH3 domain alone (a tiny spiral-shaped piece of the protein) is enough to lock into the binding groove of anti-apoptotic proteins and start a death signal.
Exam tip: The BH domain pattern is the fastest way to classify any Bcl-2 family member.
- BH1 + BH2 + BH3 + BH4 = Anti-apoptotic (pro-survival)
- BH1 + BH2 + BH3, no BH4 = Effector (pro-apoptotic, forms pores)
- BH3 only = BH3-only sensor protein (pro-apoptotic)
Quick reference:
| Protein type | BH4 | BH3 | BH1 | BH2 |
|---|---|---|---|---|
| Anti-apoptotic (BCL-2, BCL-XL, MCL-1) | ✓ | ✓ | ✓ | ✓ |
| Effector (BAX, BAK, BOK) | ✗ | ✓ | ✓ | ✓ |
| BH3-only (BIM, BID, BAD, PUMA) | ✗ | ✓ | ✗ | ✗ |
Three Subfamilies of the Bcl-2 Family
Subfamily 1: Anti-Apoptotic Guardians
Members: BCL-2, BCL-XL, MCL-1, BCL-W, A1/BFL-1
Where they sit: Mostly on the outer mitochondrial membrane (OMM).
These proteins are the survival guards. Their BH1–BH3 groove grabs and holds onto two things: the BH3-only sensor proteins and the killer effector proteins BAX and BAK. As long as BAX and BAK stay stuck in this grip, they cannot punch holes in the mitochondrial membrane. Without those holes (MOMP), cytochrome c cannot escape, caspases stay off, and the cell remains alive.
⚠️ Critical mistakes to avoid:
- BCL-2 is anti-apoptotic. It blocks cell death. Do not write it as pro-apoptotic.
- MCL-1 is also anti-apoptotic. Despite its name (Myeloid Cell Leukaemia-1), it works exactly like BCL-2 to sequester BAX/BAK.
Subfamily 2: Effector Pro-Apoptotic Proteins (The Pore Formers)
Members: BAX, BAK, BOK
These are the actual executioners at the mitochondrial membrane. They wait in an inactive state until a death signal releases them. Then they cluster together and form large holes (pores) in the outer mitochondrial membrane.
Here’s the sequence:
- BH3-only proteins (either directly or indirectly) set BAX/BAK free.
- BAX and BAK change shape and clump together on the OMM.
- These clumps form lipidic pores — this is MOMP (Mitochondrial Outer Membrane Permeabilisation), the point of no return.
- Cytochrome c and SMAC/DIABLO leak out into the cytoplasm.
- Cytochrome c teams up with Apaf-1 to build the apoptosome, which activates caspase-9 and then caspase-3 — the demolition crew.
📍 Important fact:
- BAK is always sitting on the mitochondrial membrane, even in healthy cells.
- BAX floats in the cytosol of healthy cells and only moves to the mitochondria after it gets activated.
This difference often appears in exam questions.
Subfamily 3: BH3-Only Stress Sensors (Pro-Apoptotic)
These proteins contain only the BH3 domain. Each one senses a specific stress and pushes the cell toward death. They are split into two functional groups.
Class A: Activators
Members: BIM, tBID (cut from BID), PUMA
These directly latch onto BAX and BAK, forcing them to change shape and oligomerise.
- BIM: switched on when growth factors disappear or when the ER is stressed.
- BID: cut by caspase-8 (from the extrinsic pathway) to make tBID. tBID then activates BAX/BAK, forming a direct bridge between the extrinsic and intrinsic pathways — a classic exam topic.
- PUMA: made when p53 senses DNA damage.
Class B: Sensitisers (De-repressors)
Members: BAD, NOXA, HRK, BMF
These do not directly activate BAX or BAK. Instead, they stick to the anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1) and push BAX/BAK out of the grip. That frees BAX/BAK to be activated.
- BAD: responds to loss of growth factors. It is shut off when survival signals are strong (see later).
- NOXA: also made by p53; it likes to grab MCL-1 specifically.
Exam tip: Distinguishing Activators (BIM, tBID, PUMA) from Sensitisers (BAD, NOXA) is essential for full marks. Don’t lump them all together.
Summary: Bcl-2 Family Proteins Classification
| Subfamily | Members | BH Domains | Function |
|---|---|---|---|
| Anti-apoptotic Guardians | BCL-2, BCL-XL, MCL-1, BCL-W, A1/BFL-1 | BH1, BH2, BH3, BH4 | Hold BAX/BAK and BH3-only proteins inactive; stop MOMP; keep cell alive |
| Effector Pro-apoptotic | BAX, BAK, BOK | BH1, BH2, BH3 | Form pores in OMM → MOMP → release cytochrome c → activate caspases |
| BH3-only Activators | BIM, BID (tBID), PUMA | BH3 only | Directly activate BAX/BAK; also block anti-apoptotic proteins |
| BH3-only Sensitisers | BAD, NOXA, HRK, BMF | BH3 only | Bind anti-apoptotic proteins to free BAX/BAK; do not directly activate BAX/BAK |
How Pro- and Anti-Apoptotic Members Interact
There are two models, and both happen in real cells.
The Indirect (Displacement) Model:
BAX and BAK are normally held captive by anti-apoptotic proteins. BH3-only proteins compete for that same binding groove and push BAX/BAK out. Once free, BAX/BAK spontaneously oligomerise and form pores.
The Direct Activation Model:
Activator BH3-only proteins (BIM, tBID, PUMA) physically touch BAX and BAK, changing their shape so they can oligomerise. Sensitisers help by tying up the anti-apoptotic guards, so more activators are available.
Think of it like this: anti-apoptotic proteins are handcuffs on BAX/BAK. Sensitisers steal the key, and activators pull the handcuffs off and push BAX/BAK together.
The BCL-2/BAX Ratio: The Life-Death Balance
A cell’s fate isn’t decided by one protein alone. It’s the balance that matters — often called the BCL-2/BAX ratio.
- High BCL-2/BAX ratio (cell survives): There’s plenty of anti-apoptotic protein to keep all BAX/BAK locked up. No holes form, no cytochrome c escapes.
- Low BCL-2/BAX ratio (cell dies): Too much BAX/BAK, not enough guards. Free BAX/BAK oligomerise, MOMP happens, caspases activate.
This explains why cancer cells with lots of BCL-2 are hard to kill with chemotherapy — the balance is heavily toward survival.
Post-Translational Control: The Akt–BAD Phosphorylation Switch
Survival signals from growth factors can directly switch off the death signal by modifying BAD.
When survival signals are present (cell lives):
Growth factor → PI3K → Akt (active)
Akt adds phosphate groups to BAD.
Phospho-BAD is grabbed by 14-3-3 proteins and kept in the cytoplasm.
BAD can’t reach BCL-2/BCL-XL, so BAX/BAK remain locked up → cell survives.
When growth factors are gone (cell dies):
Akt becomes inactive → a phosphatase removes the phosphate from BAD.
BAD is released from 14-3-3.
Free BAD moves to the mitochondria and binds BCL-2/BCL-XL.
BCL-2/BCL-XL are now busy, so BAX/BAK are freed → MOMP → apoptosis.
Exam tip: This Akt–phospho-BAD–14-3-3 pathway is a common 2-mark question. Always connect survival signalling directly to Bcl-2 control.
Cancer Relevance: When the Guards Go Rogue
Many cancers overexpress BCL-2 to stay alive. The classic example is follicular lymphoma, where a chromosomal translocation (t(14;18)) puts the BCL-2 gene under a powerful enhancer. BCL-2 is made in huge amounts, and the cells simply refuse to die.
Venetoclax: A Drug That Mimics BH3
Venetoclax (ABT-199) is a smart drug, its design looks exactly like a BH3 domain. It slips into the groove of BCL-2 and occupies it. That means BCL-2 can no longer hold onto BAX/BAK. In cancer cells that depend on BCL-2 for survival (like chronic lymphocytic leukaemia, CLL), this restores apoptosis.
Key Takeaways for Revision
- Three subfamilies: Anti-apoptotic guardians (BCL-2, BCL-XL, MCL-1), effectors (BAX, BAK), BH3-only sensors (BIM, BID, PUMA, BAD, NOXA).
- BH domain rule: All four = pro-survival; three (no BH4) = effector; BH3 only = sensor.
- Location matters: BAK is always on the mitochondria. BAX is cytosolic until activated.
- Activators vs Sensitisers: Activators directly touch BAX/BAK. Sensitisers only block the guards.
- The ratio: High BCL-2/BAX = survival (BAX/BAK locked); Low = apoptosis (free BAX/BAK).
- BAD switch: Akt phosphorylates BAD → 14-3-3 holds it away → BCL-2 free → cell survives. Growth factor withdrawal reverses this.
- Cancer connection: BCL-2 overexpression (lymphoma) blocks death. Venetoclax mimics BH3 to restart apoptosis.
Conclusion:
The Bcl-2 family proteins are the decision-making hub at the mitochondrial surface. Anti-apoptotic members hold the killers (BAX/BAK) in check while sensors (BH3-only proteins) bring stress signals. When death signals win — through BH3-only activation, loss of survival signals, or a bad BCL-2/BAX ratio — BAX/BAK form pores, MOMP occurs, and the cell is irreversibly commits to apoptosis.
Understanding this process forms the foundation for explaining how cancer cells evade death and how modern drugs like Venetoclax restore programmed cell death.